search
Back to results

LISH Trial for the Hepatic Flexure and Proximal Transverse Colon Cancer

Primary Purpose

Hepatic Flexure Colon Cancer, Proximal Transverse Colon Cancer

Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
LISH （Laparoscopic Ileocecal-Sparing Right Hemicolectomy）
TRH（Traditional Laparoscopic Right Hemicolectomy）
Sponsored by
Zhejiang University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hepatic Flexure Colon Cancer focused on measuring hepatic flexure colon cancer, proximal transverse colon cancer, ileocecus-sparing, laparoscopic right hemicolectomy

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age between 18-75 years old ASA classification ≤III Colon adenocarcinoma confirmed by endoscopy and pathological biopsy Enhanced abdominal CT indicating the primary lesion is located in the hepatic flexure of the colon or proximal transverse colon (proximal 1/3 of the transverse colon) Preoperative clinical staging: TanyNanyM0 Patients able to understand the study protocol, willing to participate in the research, and providing written informed consent Exclusion Criteria: Preoperative examination indicates synchronous multiple primary colorectal cancers or other diseases requiring bowel segment resection Preoperative imaging or intraoperative exploration reveals: 1) tumor involving surrounding organs requiring combined organ resection; 2) presence of distant metastasis; 3) inability to perform R0 resection; 4) fused and fixed lymph nodes at the root of the ileocolic vessels Additional radical surgery following Endoscopic Mucosal Resection (EMR) and Endoscopic Submucosal Dissection (ESD) procedures History of any other malignant tumor within the last 5 years or familial adenomatous polyposis, except for cured in situ cervical cancer, basal cell carcinoma, papillary thyroid carcinoma, or skin squamous cell carcinoma Presence of bowel obstruction, bowel perforation, or intestinal bleeding requiring emergency surgery Patients unsuitable for or unable to tolerate laparoscopic surgery Pregnant or lactating women Patients with a history of psychiatric disorders Patients who have received neoadjuvant therapy prior to surgery Patients deemed unsuitable for the study by MDT discussion Patients unable to understand the study's conditions and objectives, and refusing to sign informed consent.

Sites / Locations

  • the First Affiliated Hospital of Bengbu Medical Collage
  • Beijing Cancer HospitalRecruiting
  • Peking Union Medical College HospitalRecruiting
  • Cancer Hospital Academy of medicine SceniceRecruiting
  • the First Affiliated Hospital of Chongqing Medical CollageRecruiting
  • Fujian Cancer Hospital
  • Fujian Hospital Medical Union UniversityRecruiting
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technolog
  • Hunan Cancer Hospital
  • Jiangsu province hospital
  • Nanjing Drum Tower HospitalRecruiting
  • The First Affiliated Hospital of Nanchang University
  • The Second Affiliated Hospital of Nanchang University
  • Changhai Hospital of ShanghaiRecruiting
  • Fudan University Shanghai Cancer CenterRecruiting
  • Renji Hospital Affiliated of The Shanghai Jiao Tong University Medical School
  • Ruijin Hospital Affiliated of The Shanghai Jiao Tong University Medical School
  • Sichuan Cancer Hospital
  • West China Hospital of Sichuang UniversityRecruiting
  • The Cancer Hospital Affiliated of The Xingjiang University Medical SchoolRecruiting
  • Yunan Cancer Hospital
  • Second Affiliated Hospital Zhejiang University College of MedicineRecruiting
  • Sir Run Run Shaw Hospital, Zhejiang University School of medicienRecruiting
  • The First Affiliated Hospital, Zhejiang University school of Medicine
  • Zhejiang Cancer Hospital
  • Jinhua Municipal Central HospitalRecruiting
  • Ningbo No.2 Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

LISH （Laparoscopic Ileocecal-Sparing Right Hemicolectomy）group

TRH （Traditional Right Hemicolectomy）group

Arm Description

In LISH group, patients suffering from cancer of the hepatic flexure and proximal transverse colon will be undergoing a novel radical right hemicolectomy technique that allows for the preservation of the ileocecal region.

In TRH group, patients suffering from cancer of the hepatic flexure and proximal transverse colon will be undergoing the traditional radical right hemicolectomy.

Outcomes

Primary Outcome Measures

3-year disease free survival
the time from enrollment until disease relapse or death from any cause 3 years after surgery

Secondary Outcome Measures

Postoperative complications
Complications occurring within 30 days after surgery, classified according to the Clavien-Dindo system, including intraoperative, short-term, and long-term postoperative complications.Index (CCI) will be recorded
Metastasis rate of harvested lymph nodes
according to the pathological report
Quality of CME (complete mesocolic excision)
After the specimen had been harvested, photographs of the anterior and posterior aspects of the specimens were uploaded to the electronic data capture system. On the basis of the anterior and posterior photographs, the specimens were classified into three groups of the quality of CME: grade I, intact mesocolon; grade II laceration in the mesocolon; and grade III laceration in the mesocolon reaching the bowel.
Length of resected specimen
On the basis of the anterior and posterior photographs, the length of resected specimen were measured.
Resection margins distance
On the basis of the anterior and posterior photographs, the distal and proximal resection margins distance of the resected intestinal specimen were measured.
Vascular pedicle length of resected specimen
On the basis of the anterior and posterior photographs, the vascular pedicle length of the resected intestinal specimen were measured.
Positive margin rate
positive margin rate of resected specimen according to the pathological report
Incidence rates of polyps
the incidence rates of polyps as seen on colonoscopy at 1, 3 and 5 years after surgery respectively.
Incidence rates of adenomas
the incidence rates of adenomas as seen on colonoscopy at 1, 3 and 5 years after surgery respectively.
Scores from the Gastrointestinal Symptom Rating Scale (GSRS)
scores from the Gastrointestinal Symptom Rating Scale (GSRS) at 1, 2, and 3 years after surgery respectively.
Scores from the EQ-5D-5L Quality of Life Scale
scores from the EQ-5D-5L Quality of Life Scale at 1, 2, and 3 years after surgery respectively.
5-year overall survival rate (OS)
The proportion of patients who survived 5 years after surgery, taking into account any cause of death.

Full Information

First Posted
May 30, 2023
Last Updated
September 30, 2023
Sponsor
Zhejiang University
search

1. Study Identification

Unique Protocol Identification Number
NCT05923255
Brief Title
LISH Trial for the Hepatic Flexure and Proximal Transverse Colon Cancer
Official Title
Laparoscopic Ileocecal-Sparing Right Hemicolectomy for Cancer of the Hepatic Flexure and Proximal Transverse Colon -- A Prospective, Multicenter Randomized Control Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 14, 2023 (Actual)
Primary Completion Date
May 14, 2026 (Anticipated)
Study Completion Date
May 14, 2031 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Zhejiang University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The goal of this clinical trial is to compare the long-term outcomes of Laparoscopic Ileocecal-Sparing Right Hemicolectomy(LISH) compared to traditional laparoscopic right hemicolectomy(TRH) in the treatment of hepatic flexure colon cancer and proximal transverse colon cancer.
Detailed Description
This study is a prospective, multicenter, open-labeled, randomized controlled clinical trial. The enrolled patients will be randomly assigned to either the LISH or TRH group in a 1:1 ratio and will receive the corresponding surgery. The primary endpoint: 3-year disease free survival. The second endpoint: (1)90-day postoperative complications; (2)Pathology-related indicators, including positive margin rate, number of harvested lymph nodes and lymph node metastasis rate;(3) 5-year overall survival rate (OS)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatic Flexure Colon Cancer, Proximal Transverse Colon Cancer
Keywords
hepatic flexure colon cancer, proximal transverse colon cancer, ileocecus-sparing, laparoscopic right hemicolectomy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
568 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
LISH （Laparoscopic Ileocecal-Sparing Right Hemicolectomy）group
Arm Type
Experimental
Arm Description
In LISH group, patients suffering from cancer of the hepatic flexure and proximal transverse colon will be undergoing a novel radical right hemicolectomy technique that allows for the preservation of the ileocecal region.
Arm Title
TRH （Traditional Right Hemicolectomy）group
Arm Type
Active Comparator
Arm Description
In TRH group, patients suffering from cancer of the hepatic flexure and proximal transverse colon will be undergoing the traditional radical right hemicolectomy.
Intervention Type
Procedure
Intervention Name(s)
LISH （Laparoscopic Ileocecal-Sparing Right Hemicolectomy）
Intervention Description
Preserve the ileocolic blood vessels, and perform dissection of lymph node groups 203, 202, and 201d along the root of ICV(Ileocolic artery)/ICA(Ileocolic vein). Group 201d lymph nodes are defined as the distal lymph nodes of the ileocolic vessels (colonic branch). Use an intracavitary cutting and sealing device to transect the proximal colon along the predetermined margin, and transect the transverse colon at 10cm distal to the tumor. Perform ileocecal-transverse colonic anastomosis.
Intervention Type
Procedure
Intervention Name(s)
TRH（Traditional Laparoscopic Right Hemicolectomy）
Intervention Description
Transect the root of the ileocolic vessels and perform dissection of lymph node groups 203, 202, and 201; sever the roots of the right colic and middle colic vessels, and clear the surrounding lymphoadipose tissue (lymph node groups 211/212/213 and 221/222/223). Transect the transverse colon 10cm distal to the tumor and cut the terminal ileum 10cm from the ileocecal junction. Perform ileum-to-transverse colon anastomosis.
Primary Outcome Measure Information:
Title
3-year disease free survival
Description
the time from enrollment until disease relapse or death from any cause 3 years after surgery
Time Frame
3 years
Secondary Outcome Measure Information:
Title
Postoperative complications
Description
Complications occurring within 30 days after surgery, classified according to the Clavien-Dindo system, including intraoperative, short-term, and long-term postoperative complications.Index (CCI) will be recorded
Time Frame
up to 30 days after surgery
Title
Metastasis rate of harvested lymph nodes
Description
according to the pathological report
Time Frame
up to 2 weeks after surgery
Title
Quality of CME (complete mesocolic excision)
Description
After the specimen had been harvested, photographs of the anterior and posterior aspects of the specimens were uploaded to the electronic data capture system. On the basis of the anterior and posterior photographs, the specimens were classified into three groups of the quality of CME: grade I, intact mesocolon; grade II laceration in the mesocolon; and grade III laceration in the mesocolon reaching the bowel.
Time Frame
up to 2 weeks after surgery
Title
Length of resected specimen
Description
On the basis of the anterior and posterior photographs, the length of resected specimen were measured.
Time Frame
up to 2 weeks after surgery
Title
Resection margins distance
Description
On the basis of the anterior and posterior photographs, the distal and proximal resection margins distance of the resected intestinal specimen were measured.
Time Frame
up to 2 weeks after surgery
Title
Vascular pedicle length of resected specimen
Description
On the basis of the anterior and posterior photographs, the vascular pedicle length of the resected intestinal specimen were measured.
Time Frame
up to 2 weeks after surgery
Title
Positive margin rate
Description
positive margin rate of resected specimen according to the pathological report
Time Frame
up to 2 weeks after surgery
Title
Incidence rates of polyps
Description
the incidence rates of polyps as seen on colonoscopy at 1, 3 and 5 years after surgery respectively.
Time Frame
5 years
Title
Incidence rates of adenomas
Description
the incidence rates of adenomas as seen on colonoscopy at 1, 3 and 5 years after surgery respectively.
Time Frame
5 years
Title
Scores from the Gastrointestinal Symptom Rating Scale (GSRS)
Description
scores from the Gastrointestinal Symptom Rating Scale (GSRS) at 1, 2, and 3 years after surgery respectively.
Time Frame
3 years
Title
Scores from the EQ-5D-5L Quality of Life Scale
Description
scores from the EQ-5D-5L Quality of Life Scale at 1, 2, and 3 years after surgery respectively.
Time Frame
3 years
Title
5-year overall survival rate (OS)
Description
The proportion of patients who survived 5 years after surgery, taking into account any cause of death.
Time Frame
5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age between 18-75 years old ASA classification ≤III Colon adenocarcinoma confirmed by endoscopy and pathological biopsy Enhanced abdominal CT indicating the primary lesion is located in the hepatic flexure of the colon or proximal transverse colon (proximal 1/3 of the transverse colon) Preoperative clinical staging: TanyNanyM0 Patients able to understand the study protocol, willing to participate in the research, and providing written informed consent Exclusion Criteria: Preoperative examination indicates synchronous multiple primary colorectal cancers or other diseases requiring bowel segment resection Preoperative imaging or intraoperative exploration reveals: 1) tumor involving surrounding organs requiring combined organ resection; 2) presence of distant metastasis; 3) inability to perform R0 resection; 4) fused and fixed lymph nodes at the root of the ileocolic vessels Additional radical surgery following Endoscopic Mucosal Resection (EMR) and Endoscopic Submucosal Dissection (ESD) procedures History of any other malignant tumor within the last 5 years or familial adenomatous polyposis, except for cured in situ cervical cancer, basal cell carcinoma, papillary thyroid carcinoma, or skin squamous cell carcinoma Presence of bowel obstruction, bowel perforation, or intestinal bleeding requiring emergency surgery Patients unsuitable for or unable to tolerate laparoscopic surgery Pregnant or lactating women Patients with a history of psychiatric disorders Patients who have received neoadjuvant therapy prior to surgery Patients deemed unsuitable for the study by MDT discussion Patients unable to understand the study's conditions and objectives, and refusing to sign informed consent.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kefeng Ding, PhD
Phone
86-571-87784720
Email
dingkefeng@zju.edu.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kefeng Ding, PhD
Organizational Affiliation
Second Affiliated Hospital, School of Medicine, Zhejiang University
Official's Role
Principal Investigator
Facility Information:
Facility Name
the First Affiliated Hospital of Bengbu Medical Collage
City
Bengbu
State/Province
Anhui
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Muling Liu, phD
First Name & Middle Initial & Last Name & Degree
Muling Liu, phD
Facility Name
Beijing Cancer Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Aiwen Wu, PhD
First Name & Middle Initial & Last Name & Degree
Xiangqian Su, PhD
First Name & Middle Initial & Last Name & Degree
Aiwen Wu, PhD
First Name & Middle Initial & Last Name & Degree
Xiangqian Su, PhD
Facility Name
Peking Union Medical College Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yi Xiao, PhD
First Name & Middle Initial & Last Name & Degree
Yi Xiao, PhD
Facility Name
Cancer Hospital Academy of medicine Scenice
City
Beijing
State/Province
Beijing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Qian Liu, phD
First Name & Middle Initial & Last Name & Degree
Xishan Wang
First Name & Middle Initial & Last Name & Degree
Qian Liu, phD
First Name & Middle Initial & Last Name & Degree
Xishan Wang, phD
Facility Name
the First Affiliated Hospital of Chongqing Medical Collage
City
Chongqing
State/Province
Chongqing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhengqiang Wei, phD
First Name & Middle Initial & Last Name & Degree
Zhengqiang Wei, phD
Facility Name
Fujian Cancer Hospital
City
Fuzhou
State/Province
Fujian
ZIP/Postal Code
350001
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chunkang Yang, PhD
First Name & Middle Initial & Last Name & Degree
Chunkang Yang, MD
Facility Name
Fujian Hospital Medical Union University
City
Fuzhou
State/Province
Fujian
ZIP/Postal Code
350001
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pan Chi
First Name & Middle Initial & Last Name & Degree
Pan Chi, M.D.
Facility Name
Union Hospital, Tongji Medical College, Huazhong University of Science and Technolog
City
Wuhan
State/Province
Hubei
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kaixiong Tao, phD
First Name & Middle Initial & Last Name & Degree
Kaixiong Tao, phD
Facility Name
Hunan Cancer Hospital
City
Changsha
State/Province
Hunan
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhigang Xiao, phD
First Name & Middle Initial & Last Name & Degree
Zhongcheng Huang, phD
First Name & Middle Initial & Last Name & Degree
Zhigang Xiao, phD
Facility Name
Jiangsu province hospital
City
Nanjing
State/Province
Jiangsu
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yueming Sun, phD
First Name & Middle Initial & Last Name & Degree
Yueming Sun, phD
Facility Name
Nanjing Drum Tower Hospital
City
Nanjing
State/Province
Jiangsu
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gang Chen, phD
First Name & Middle Initial & Last Name & Degree
Gang Chen, phD
Facility Name
The First Affiliated Hospital of Nanchang University
City
Nanchang
State/Province
Jiangxi
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Taiyuan Li, phD
First Name & Middle Initial & Last Name & Degree
Taiyuan Li, phD
Facility Name
The Second Affiliated Hospital of Nanchang University
City
Nanchang
State/Province
Jiangxi
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shengxun Mao, phD
First Name & Middle Initial & Last Name & Degree
Shengxun Mao, phD
Facility Name
Changhai Hospital of Shanghai
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200433
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wei Zhang
First Name & Middle Initial & Last Name & Degree
Wei Zhang, MD
Facility Name
Fudan University Shanghai Cancer Center
City
Shanghai
State/Province
Shanghai
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ye Xu, phD
First Name & Middle Initial & Last Name & Degree
Xinxiang Li, phD
First Name & Middle Initial & Last Name & Degree
Ye Xu, phD
First Name & Middle Initial & Last Name & Degree
Xinxiang Li, phD
Facility Name
Renji Hospital Affiliated of The Shanghai Jiao Tong University Medical School
City
Shanghai
State/Province
Shanghai
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ming Zhong, phD
First Name & Middle Initial & Last Name & Degree
Ming Zhong, phD
Facility Name
Ruijin Hospital Affiliated of The Shanghai Jiao Tong University Medical School
City
Shanghai
State/Province
Shanghai
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bo Feng, phD
First Name & Middle Initial & Last Name & Degree
Bo Feng, phD
Facility Name
Sichuan Cancer Hospital
City
Chengdu
State/Province
Sichuan
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jin Yan, phD
First Name & Middle Initial & Last Name & Degree
Jin Yan, phD
Facility Name
West China Hospital of Sichuang University
City
Chengdu
State/Province
Sichuan
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ziqiang Wang, phD
First Name & Middle Initial & Last Name & Degree
Ziqiang Wang, phD
Facility Name
The Cancer Hospital Affiliated of The Xingjiang University Medical School
City
Xinjiang
State/Province
Xinjiang
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Haijiang Wang, phD
First Name & Middle Initial & Last Name & Degree
Haijiang Wang, phD
Facility Name
Yunan Cancer Hospital
City
Kunming
State/Province
Yunnan
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yunfeng Li, phD
First Name & Middle Initial & Last Name & Degree
Yunfeng Li, phD
Facility Name
Second Affiliated Hospital Zhejiang University College of Medicine
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310999
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ke-Feng Ding, phD/MD
Phone
86-571-87784827
Email
dingkefeng@zju.edu.cn
First Name & Middle Initial & Last Name & Degree
Ke-Feng Ding, phD/MD
Facility Name
Sir Run Run Shaw Hospital, Zhejiang University School of medicien
City
Hangzhou
State/Province
Zhejiang
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xuefeng Huang, phD
First Name & Middle Initial & Last Name & Degree
Xuefeng Huang, phD
Facility Name
The First Affiliated Hospital, Zhejiang University school of Medicine
City
Hangzhou
State/Province
Zhejiang
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wenbin Chen, phD
First Name & Middle Initial & Last Name & Degree
Wenbin Chen, phD
Facility Name
Zhejiang Cancer Hospital
City
Hangzhou
State/Province
Zhejiang
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Haixing Ju, phD
First Name & Middle Initial & Last Name & Degree
Haixing Ju, phD
Facility Name
Jinhua Municipal Central Hospital
City
Jinhua
State/Province
Zhejiang
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jinlin Du, phD
First Name & Middle Initial & Last Name & Degree
Jinlin Du, phD
Facility Name
Ningbo No.2 Hospital
City
Ningbo
State/Province
Zhejiang
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xiaoyu Dai, phD
First Name & Middle Initial & Last Name & Degree
Xiaoyu Dai, phD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

LISH Trial for the Hepatic Flexure and Proximal Transverse Colon Cancer

We'll reach out to this number within 24 hrs